Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00364221 · ClinicalTrials.gov registry record · Phase 4
Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome
A Phase 4 study of Insulin Resistance and Metabolic Syndrome, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 1
- Study location
NCT00364221 is a Phase 4 study of Insulin Resistance and Metabolic Syndrome that has completed, run by University of Colorado, Denver. The trial reports 1 study location across 1 state.
The verdict
NCT00364221, a Phase 4 study of Insulin Resistance and Metabolic Syndrome, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1
- Study location
Study Summary
The metabolic syndrome is a collection of health risks that includes obesity, high blood pressure, high triglycerides, high blood sugar, low good cholesterol, and resistance to insulin. The purpose of this study is to find out if the medication, rosiglitazone, influences levels of fat cell proteins and alters insulin resistance in nondiabetic persons with the metabolic syndrome. This is an early step to see if a medication, such as rosiglitazone, will be beneficial in people who have the metabolic syndrome.
Conditions Studied
Interventions
- DRUG Rosiglitazone
Study Locations (1)
Colorado
- University of Colorado at Denver and Health Sciences Center General Clinical Research Center - Denver
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-11 |
| Est. Completion | 2006-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00364221
The ClinicalTrials.gov registry entry for NCT00364221 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which Rosiglitazone is the first listed.
NCT00364221 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT00364221 about?
NCT00364221 is a clinical study titled "Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome". The metabolic syndrome is a collection of health risks that includes obesity, high blood pressure, high triglycerides, high blood sugar, low good cholesterol, and resistance to insulin. The purpose of this study is to find out if the medication, rosiglitazone, influences levels of fat cell proteins ...
What is the current status of trial NCT00364221?
This trial is currently completed. It is a Phase 4 study. The study started on 2004-11. Estimated completion is 2006-10.
What conditions does trial NCT00364221 study?
This clinical trial studies the following conditions: Insulin Resistance, Metabolic Syndrome.
What interventions are being tested in trial NCT00364221?
The interventions under investigation include: Rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00364221?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00364221 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
COMPLETED · Phase 4
-
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
COMPLETED · Phase 4
-
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
COMPLETED · Phase 4
-
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
COMPLETED · Phase 4
-
Pioglitazone in Patients With Mood Disorders
COMPLETED · Phase 4
-
Oral Contraceptives in the Metabolic Syndrome
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.